TAG:
pathology market
AmeriPath, Cytyc, NeoPath, Morphometrix, AutoCyte
By Robert Michel | From the Volume VI No. 4 – March 15, 1999 Issue
AMERIPATH REPORTS RECORD YEAR & LOSES ITS CHAIRMAN MIXED SIGNALS RECENTLY EMERGED from AmeriPath, Inc., the country’s largest pathology PPM. It finished the year with strong financials and lost its chairman. On one hand, it finished its first full year as a public com…
“May 26, 1998 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume V No. 7 – May 26, 1998 Issue
Another pathologybased PPM received venture capital funding. Pathology Consultants of America, (PCA) based in Nashville, Tennessee, just closed a $16 million deal with two venture capitalists. ABS Capital Partners of Baltimore invested $15 million. An affiliate of …
American Path Resources Bought By Pathology PPM
By Robert Michel | From the Volume V No. 5 – April 13, 1998 Issue
CEO SUMMARY: Here is first confirmation that Pathology Consultants of America has indeed purchased American Pathology Resources. The combination of the two pathology-based physician practice management companies demonstrates that the pathology industry is on the verge of rapid transformat…
Pathology PPM Appears Ready To Hit Marketplace
By Robert Michel | From the Volume V No. 5 – April 13, 1998 Issue
CEO SUMMARY: After several months of delays, Physician Solutions recruited a new CEO and completed arrangements to receive $20 million in venture capital funding. These two milestones mean that the pathology-based physician practice management company will soon be ready to launch formal b…
DIANON Systems Acquires Pathology Lab In Florida
By Robert Michel | From the Volume V No. 3 – March 2, 1998 Issue
CEO SUMMARY: Another national pathology player is betting on Florida. DIANON Systems, Inc.’s purchase of a local pathology laboratory raises the competitive bar in Florida. With AmeriPath and Pathology Service Associates already gearing up to battle for market share, DIANON’s local pr…
Pathology Competitors Make Florida The Target
By Robert Michel | From the Volume V No. 3 – March 2, 1998 Issue
CEO SUMMARY: Florida is about to become the marketing battleground for anatomic pathology. Three well-funded players are preparing to launch major sales efforts. Pathologists in the state wait with trepidation. Expectations of discounted pricing and a “gloves-off” sales strategy conce…
To Protect Pathology Profits: Understand Managed Care
By Robert Michel | From the Volume IV No. 18 – December 29, 1997 Issue
CEO SUMMARY: On November 8, 1997, THE DARK REPORT convened a private symposium restricted only to pathologists. The sole purpose of this event was to identify how pathologists could preserve and enhance their income. Within the confidential setting of a plush resort in Scottsdale, Arizona…
AmeriPath Successfully Completes Public Offering
By Robert Michel | From the Volume IV No. 15 – October 27, 1997 Issue
CEO SUMMARY: AmeriPath’s new status as a public company gives it even greater visibility than before. As the first public pathology-based physician practice management firm, AmeriPath has the potential to introduce many innovations into the business organization of pathology services. W…
Physician Management Companies Exploding, Will Transform Healthcare
By Robert Michel | From the Volume IV No. 10 – July 14, 1997 Issue
CEO SUMMARY: Consolidation and integration of healthcare services will be the dominant trend during the next five years. It happened to commercial laboratories from 1985-95. Widespread hospital consolidation began around 1990 and continues today. Now consolidation is coming to physicians….
AmeriPath Stock Offering Pulled By Underwriters
By Robert Michel | From the Volume IV No. 6 – April 21, 1997 Issue
CEO SUMMARY: Ameripath planned to go public in March. However, the stock market’s significant decline and further evaluation of the company’s business plan caused Wall Street underwriters to defer issuing the stock. Pathologists are curious as to whether AmeriPath’s “employee” b…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized